Ventuno Biotech

Ventuno Biotech is an early-stage, privately-held biotech developing innovative antibody-based immunotherapies for oncology. Founded in 2018 and based in Paris, the company is backed by seed funding and non-dilutive grants from French public institutions like Bpifrance. Led by a team with deep expertise in oncology, immunology, and biotech operations, Ventuno is in the preclinical research phase, building its pipeline and platform. Its strategy leverages strong academic ties and a focus on novel targets to address unmet needs in cancer care.

Focus on discovery and development of therapeutic antibodies for immuno-oncology, leveraging expertise in immunology, translational research, and preclinical models to target novel mechanisms in difficult-to-treat cancers.

Ventuno operates in the highly competitive global immuno-oncology field, competing against large pharma and numerous biotechs developing next-generation checkpoint inhibitors, bispecific antibodies, and cell therapies. Its differentiation hinges on the novelty and potency of its undiscovered targets and its ability to rapidly translate academic insight into drug candidates.